Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study
K. Suzuki, Takeharu Yamanaka, Hiroki Hashimoto et al. · Annals of Oncology · 2016
Cited by 92 works. doi:10.1093/annonc/mdw220 Open-access PDF
Authors
- Takeharu Yamanaka
- Hiroki Hashimoto
- Yoshifumi Shimada
- Koji Arata
- Reiko Matsui
- Kōichi Goto
- Tomomi Takiguchi
- Fumiyoshi Ohyanagi
- Yuki Kogure
- Naoyuki Nogami
- Masahiko Nakao
- Kanako Azuma
- Toshinobu Hayashi
- Nobuyuki Yamamoto
References
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
- The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
- Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting
- Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
- Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.
- Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
- Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.
- Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis
- Nausea : Mechanisms and Management
- Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting